College of American Pathologists
Printable Version



CAP Today




September 2011

bullet microRNA

Unfortunately, we at Rosetta Genomics observed an error in your article “MicroRNA—is the contender a champ?” (August 2011) in the sentence that says: “Most of the work on Rosetta’s microRNA assays has been presented only in poster form.” Rosetta Genomics takes great pride in its ability to publish its scientific work. Since 2010 Rosetta has published 12 manuscripts in distinguished peer-reviewed journals; eight of those manuscripts (three cited in your article) describe the discovery, development, validation, and post-marketing studies of its products. The sentence should have said that most of the work on Rosetta’s microRNA assays has been published in peer-reviewed journals.

The relevant citations related to Rosetta’s commercial tests are as follows:

miRview mets: Rosenfeld N, et al. Nat Biotechnol. 2008;26:462–469; Rosenwald S, et al. Mod Pathol. 2010; 23:814–823; Mueller WC, et al. Oncologist. 2011;16:165–174; and Varadhachary GR, et al. Clin Cancer Res. 2011; Jun 15; 17(12):4063–4070.

miRview squamous: Lebanony D, et al. J Clin Oncol. 2009;27:2030–2037; Bishop JA, et al. Clin Cancer Res. 2010; Jan 15; 16(2):610–619.

miRview meso: Benjamin H, et al. J Mol Diagn. 2010;12(6):771–779.

miRview kidney: Fridman E, et al. J Mol Diagn. 2010;12(5):687–696.

Kenneth A. Berlin
President and CEO
Rosetta Genomics